on May 8, 2013 |
Permalink
Topics: Cardiovascular, Service Lines, Business Development, Strategy, Technology Assessment, Planning
Megan Tooley, Cardiovascular Roundtable
The decision to pursue transcatheter aortic valve replacement (TAVR) should not be taken lightly—we’ve been helping walk members through the considerations in our recent publication Blueprint for Valve Centers, executive summary webconference, and recent coverage in Cardiovascular Rounds.
But for some progressive institutions, TAVR is the right choice both to fill a clinical need in the community, as well as grow the CV program. So once you’ve made that decision, where do you go from there?
For a quick primer on the top investments to consider when starting a program, we turned to CV leaders at Exempla Saint Joseph Hospital, a 384-bed hospital in Denver, Colorado, who successfully launched a TAVR program last fall.
Read on for three key pieces of advice Saint Joseph Hospital has for institutions looking to launch their own TAVR program.
Continue reading:
You've decided to launch a TAVR program...now what?
on January 30, 2013 |
Permalink
Topics: Cardiac Cath, Cardiovascular, Service Lines, Vascular, Technology Assessment, Planning, Strategy
Nicole MacMillan, Cardiovascular Roundtable
Recently, a new treatment for drug-resistant hypertension known as renal denervation (RDN) has been a hot topic in the CV world. Also known as renal nerve ablation, the procedure has enormous potential to improve treatment for a large portion of the more than 68 million hypertensive patients in the United States, and may have a similarly dramatic impact for CV programs once it's approved by the FDA.
Continue reading:
Why the hype surrounding renal denervation?
on January 14, 2013 |
Permalink
Topics: Cardiovascular, Service Lines, Cardiac Cath, Cardiac Surgery, Regionalization and Networks, Strategy, Service Line Growth, Volume Growth, Technology Assessment, Planning, Program Infrastructure, Business Development
Megan Tooley, Cardiovascular Roundtable
There is no question the emergence of transcatheter valve technologies—specifically transcatheter aortic valve replacement (TAVR)—has elicited unprecedented excitement from the cardiovascular community in recent years. However, despite this enthusiasm, the reality is only a portion of hospitals will meet the strict resource and volume requirements necessary to become TAVR sites in the near future.
This may leave many of you wondering, “So what if we’re not a TAVR program? Is there still a place for us in the valve market?” You’re not alone, and as we explore in our national meeting series, your options for treating valve disease and disorders do not end at TAVR.
Learn how one Roundtable member is ensuring their patients have access to a full range of valve services—even if they’re not the TAVR program.
Continue reading:
So you're not a TAVR program—Now what?
